Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma appoints head of regulatory affairs

Rizwana Sproule joins from Amgen
Kite Pharma Rizwana Sproule

Kite Pharma has appointed former Amgen executive director Dr Rizwana Sproule as head VP, regulatory affairs.

Dr Sproule spent 14 year at Amgen, most recently serving as executive director, therapeutic area head for oncology global regulatory affairs.

In this role, she oversaw Amgen's oncology products having previously held the role of global regulatory leader for the development of Amgen's Vectibix (panitumumab), which is approved to treat colorectal cancer.

Her experience prior to joining Amgen includes a regulatory affairs consultant role at the clinical research organisation (CRO) Kendle, as well as roles at SmithKline Beecham and Syntex.

Kite's chairman Dr Arie Belldegrun said: "Rizwana offers an impressive track record in guiding the regulatory process for well-recognised best-in-class therapies, and her expertise in working with international agencies – FDA, EMA/CHMP, Health Canada, and PMDA – at multiple levels will be critical to Kite's further advancement and planning.”

Dr Sproule is the latest in a string of senior appointments at Kite as the company prepares for the advance of its research projects involving cancer immunotherapies.

Other recent additions include chief financial officer Cynthia Butitta; Dr Keith Nolop as chief medical officer; and several cancer experts to the company's scientific advisory board.

22nd January 2014

From: Regulatory

Share

Tags

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...